KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs in the United States. The company's lead product candidates include KP415 and KP484, which are extended release prodrugs of methylphenidate for the treatment of attention deficit hyperactivity disorder. It also provides APADAZ, an immediate-release (IR) combination product candidate of benzhydrocodone and acetaminophen to treat the short-term management of acute pain. In addition, the company develops KP201/IR, an acetaminophen-free immediate-release formulation of APADAZ for treating short-term management of acute pain; and KP511/ER and KP511/IR hydromorphone product candidates for the treatment of pain. Further, it is developing KP606, a prodrug of oxycodone for the management of moderate to severe pain; KP746, a prodrug of oxymorphone for the management of moderate to severe pain; and KP303, a prodrug of quetiapine for the treatment of central nervous system disorders. The company has a collaboration agreement with twoXAR, Inc. to develop prodrug-based therapies for multiple therapeutic areas and indications. The company was founded in 2006 and is headquartered in Celebration, Florida.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone321-939-3416
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date5/9/2019 (Estimated)
OptionableOptionable
KemPharm (NASDAQ:KMPH) Frequently Asked Questions
What is KemPharm's stock symbol?
KemPharm trades on the NASDAQ under the ticker symbol "KMPH."
How were KemPharm's earnings last quarter?
KemPharm Inc (NASDAQ:KMPH) issued its earnings results on Friday, August, 10th. The specialty pharmaceutical company reported ($0.65) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.96) by $0.31. View KemPharm's Earnings History.
When is KemPharm's next earnings date?
What price target have analysts set for KMPH?
6 analysts have issued 1-year price targets for KemPharm's stock. Their forecasts range from $10.00 to $17.00. On average, they expect KemPharm's stock price to reach $12.00 in the next year. This suggests a possible upside of 506.1% from the stock's current price. View Analyst Price Targets for KemPharm.
What is the consensus analysts' recommendation for KemPharm?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for KemPharm in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for KemPharm.
What are Wall Street analysts saying about KemPharm stock?
Here are some recent quotes from research analysts about KemPharm stock:
- 1. According to Zacks Investment Research, "KemPharm Inc. is a specialty pharmaceutical company which is engaged in the discovery and development of new molecular entity prodrugs. Its product candidates include KP201/APAP, KP511/ER and KP606/ER for the treatment of pain; KP415 for the treatment of attention deficit hyperactivity disorder and KP303 for the treatment of central nervous system disorders, which are in preclinical trail stage. The Company through its LAT platform technology generate prodrug. KemPharm Inc. is based in CORALVILLE, United States. " (1/15/2019)
- 2. Canaccord Genuity analysts commented, "We are encouraged by KemPharm’s progress with the ADHD program, and believe it represents a significant value-creating opportunity in the coming quarters. We maintain our BUY rating and $11 PT on KMPH shares. Positive IV Human Abuse Potential data bode well for upcoming ADHD reads. KemPharm announced positive results for their KP415 human abuse study, showing drug liking scores similar to placebo when administered up to the highest safest dose. There was no significant difference in mean and placebo. However, there was a numerically significant difference in mean and d-methylphenidate at equimolar doses. Drug liking is a proxy for the potential for drug abuse." (5/10/2018)
Has KemPharm been receiving favorable news coverage?
Press coverage about KMPH stock has been trending somewhat negative on Saturday, InfoTrie reports. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. KemPharm earned a media sentiment score of -1.5 on InfoTrie's scale. They also assigned media stories about the specialty pharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the near future.
Who are some of KemPharm's key competitors?
Some companies that are related to KemPharm include Proteostasis Therapeutics (PTI), Aldeyra Therapeutics (ALDX), Ardelyx (ARDX), Synlogic (SYBX), Molecular Templates (MTEM), Arbutus Biopharma (ABUS), VBI Vaccines (VBIV), Galmed Pharmaceuticals (GLMD), REDHILL BIOPHAR/S (RDHL), TAIWAN LIPOSOME/S (TLC), Aratana Therapeutics (PETX), Paratek Pharmaceuticals (PRTK), Millendo Therapeutics (MLND), BELLUS Health (BLUSF) and Menlo Therapeutics (MNLO).
What other stocks do shareholders of KemPharm own?
Who are KemPharm's key executives?
KemPharm's management team includes the folowing people:
- Dr. Travis C. Mickle, Co-Founder, Chairman, Pres & CEO (Age 46)
- Mr. Daniel L. Cohen, Exec. VP of Gov. & PR (Age 60)
- Dr. Sven Guenther, Exec. VP of R&D (Age 47)
- Ms. Christal M. M. Mickle, Co-Founder and VP of Operations & Product Devel. (Age 40)
- Mr. R. LaDuane Clifton CPA, CFO, Sec. & Treasurer (Age 47)
When did KemPharm IPO?
(KMPH) raised $60 million in an initial public offering (IPO) on Thursday, April 16th 2015. The company issued 4,600,000 shares at $12.00-$14.00 per share. Cowen and Company and RBC Capital Markets served as the underwriters for the IPO and Canaccord Genuity and Oppenheimer were co-managers.
Who are KemPharm's major shareholders?
KemPharm's stock is owned by a number of of institutional and retail investors. Top institutional investors include Arete Wealth Advisors LLC (2.04%), Victory Capital Management Inc. (0.91%), Geode Capital Management LLC (0.65%), Geode Capital Management LLC (0.65%), BlackRock Inc. (0.34%) and Northern Trust Corp (0.16%). Company insiders that own KemPharm stock include Daniel L Cohen, Delaware Street Capital Master, Gordon K Johnson, R Laduane Clifton, Timothy J Sangiovanni and Travis C Mickle. View Institutional Ownership Trends for KemPharm.
Which institutional investors are buying KemPharm stock?
KMPH stock was bought by a variety of institutional investors in the last quarter, including Geode Capital Management LLC, Geode Capital Management LLC, Victory Capital Management Inc., Change Path LLC, Arete Wealth Advisors LLC, Janney Montgomery Scott LLC, BlackRock Inc. and Northern Trust Corp. Company insiders that have bought KemPharm stock in the last two years include Daniel L Cohen, Delaware Street Capital Master, Gordon K Johnson, R Laduane Clifton, Timothy J Sangiovanni and Travis C Mickle. View Insider Buying and Selling for KemPharm.
How do I buy shares of KemPharm?
Shares of KMPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is KemPharm's stock price today?
One share of KMPH stock can currently be purchased for approximately $1.98.
How big of a company is KemPharm?
KemPharm has a market capitalization of $52.83 million. The specialty pharmaceutical company earns $-56,470,000.00 in net income (profit) each year or ($2.49) on an earnings per share basis.
What is KemPharm's official website?
How can I contact KemPharm?
KemPharm's mailing address is 1180 Celebration Boulevard Suite 103, Celebration FL, 34747. The specialty pharmaceutical company can be reached via phone at 321-939-3416 or via email at [email protected]
MarketBeat Community Rating for KemPharm (NASDAQ KMPH)
MarketBeat's community ratings are surveys of what our community members think about KemPharm and other stocks. Vote "Outperform" if you believe KMPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KMPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
